Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
出版年份 2022 全文链接
标题
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
作者
关键词
-
出版物
Cell Reports Medicine
Volume 3, Issue 12, Pages 100850
出版商
Elsevier BV
发表日期
2022-11-17
DOI
10.1016/j.xcrm.2022.100850
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases
- (2022) Jerome Hadjadj et al. ANNALS OF THE RHEUMATIC DISEASES
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
- (2022) Wilfredo F. Garcia-Beltran et al. CELL
- Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
- (2022) Bo Meng et al. NATURE
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2022) Delphine Planas et al. NATURE
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
- (2022) Juan Manuel Carreño et al. NATURE
- Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
- (2022) Elisabetta Cameroni et al. NATURE
- SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
- (2022) Kenrie P. Y. Hui et al. NATURE
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- (2022) Raquel Viana et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- (2022) Lihong Liu et al. NATURE
- An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
- (2022) Laura A. VanBlargan et al. NATURE MEDICINE
- Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
- (2022) Eddy Pérez-Then et al. NATURE MEDICINE
- Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
- (2022) Emi Takashita et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
- (2022) Guillaume Beaudoin-Bussières et al. Cell Reports
- Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
- (2022) Robert Stuver et al. CANCER CELL
- Antibody-mediated neutralization of SARS-CoV-2
- (2022) Henning Gruell et al. IMMUNITY
- Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant
- (2022) Ilies Benotmane et al. KIDNEY INTERNATIONAL
- Antibody evasion properties of SARS-CoV-2 Omicron sublineages
- (2022) Sho Iketani et al. NATURE
- Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
- (2022) Timothée Bruel et al. NATURE MEDICINE
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
- (2022) Myron J. Levin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
- (2022) Jingyou Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
- (2022) Franck Touret et al. Scientific Reports
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
- (2022) Kathryn Westendorf et al. Cell Reports
- Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
- (2022) Takuya Tada et al. EBioMedicine
- Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope
- (2022) Garry Dolton et al. CELL
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
- (2022) Aekkachai Tuekprakhon et al. CELL
- Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
- (2022) Guillaume Martin-Blondel et al. JOURNAL OF INFECTION
- Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
- (2022) Daichi Yamasoba et al. LANCET INFECTIOUS DISEASES
- A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
- (2022) Maxime Hentzien et al. LANCET INFECTIOUS DISEASES
- Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
- (2022) Qian Wang et al. NATURE
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
- (2022) Yunlong Cao et al. NATURE
- Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
- (2022) Houriiyah Tegally et al. NATURE MEDICINE
- Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
- (2022) Emi Takashita et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
- (2022) Brian J. Willett et al. Nature Microbiology
- Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
- (2022) Prerna Arora et al. LANCET INFECTIOUS DISEASES
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
- (2021) Emma S. Winkler et al. CELL
- Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2
- (2021) Ludivine Grzelak et al. JOURNAL OF INFECTIOUS DISEASES
- Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection
- (2021) Stéphane Pelleau et al. JOURNAL OF INFECTIOUS DISEASES
- Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
- (2021) Rachel Yamin et al. NATURE
- Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
- (2021) Florian A. Lempp et al. NATURE
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- (2021) Michael Dougan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
- (2021) Meagan P. O’Brien et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- (2021) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- (2021) Anil Gupta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Syncytia formation by SARS‐CoV‐2 infected cells
- (2020) Julian Buchrieser et al. EMBO JOURNAL
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- (2020) Delphine Sterlin et al. Science Translational Medicine
- HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
- (2016) T. Schoofs et al. SCIENCE
- Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
- (2015) Mireia Pelegrin et al. TRENDS IN MICROBIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now